(24/7 MARKET NEWS) – Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) reported, this morning, that it entered into a platform research evaluation collaboration and option agreement with Regeneron Pharmaceuticals, Inc., in which Xeris will use its proprietary drug-formulation platform, XeriJect, to develop ultra-highly concentrated, ready-to-use, small volume subcutaneous injections of two undisclosed monoclonal antibodies (mAbs) developed by Regeneron. Xeris will receive an upfront payment and potential milestone payments for preclinical achievements.
Xeris Biopharma is trading at $1.44, up $0.12 (+9.09%), on 60 thousand premarket shares.
Its 52-week trading range is $0.9701 to $2.72 Its next key resistance point is $1.56.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
